Related Experiment Videos
The pharmacokinetics of meropenem in infants and children: a population analysis
E M Parker1, M Hutchison, J L Blumer
1Zeneca Pharmaceuticals, Mereside, Macclesfield, Cheshire, UK.
Insights
Population pharmacokinetics analysis revealed that meropenem clearance in infants and children is primarily determined by creatinine clearance and age. Body weight significantly influences meropenem distribution, with notable differences in younger or lighter patients.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Pharmacokinetics
Background:
- Meropenem is a broad-spectrum antibiotic crucial for treating serious bacterial infections in pediatric patients.
- Understanding meropenem pharmacokinetics in infants and children is essential for optimizing therapeutic efficacy and minimizing toxicity.
- Existing pharmacokinetic data in pediatric populations are often limited, necessitating further investigation.
Purpose of the Study:
- To characterize the population pharmacokinetics of meropenem in infants and children.
- To identify key demographic factors influencing meropenem clearance and volume of distribution.
- To inform potential adjustments in meropenem dosing strategies for pediatric patients.
Main Methods:
- Analysis of plasma meropenem concentration-time data from a single-dose pharmacokinetic study.
- Utilized the population pharmacokinetics program NONMEM for data analysis.
- Employed a two-compartment open pharmacokinetic model with zero-order infusion.
Main Results:
- Creatinine clearance was the primary determinant of meropenem clearance, with age showing a significant nonlinear influence.
- Body weight was the most critical factor for the volume of distribution in both central and peripheral compartments.
- Distributional clearance exhibited a nonlinear relationship with body weight, differing notably in younger (<2 years) or lighter (<10 kg) patients.
Conclusions:
- Meropenem pharmacokinetics in pediatric patients are significantly influenced by creatinine clearance, age, and body weight.
- Younger and lighter pediatric patients demonstrate distinct pharmacokinetic parameters compared to older children.
- These findings may have implications for refining meropenem dosage recommendations in vulnerable pediatric populations, especially for drugs with narrow therapeutic indices.
Abstract:
Plasma meropenem concentration versus time data collected during a single dose, pharmacokinetic study in infants and children were analysed using the population pharmacokinetics program NONMEM. A total of 300 meropenem concentrations was obtained from 65 patients ranging from 2 months to 12 years of age; weighing between 3.7 and 46 kg. A two-compartment open pharmacokinetic model with a zero-order infusion over 30 min was fitted to the data. The most important determinant of meropenem clearance was the creatinine clearance but an additional improvement occurred when a nonlinear dependence upon age was included. The most important determinant of the volume of distribution in the central and peripheral compartments was the body weight. The distributional clearance showed a nonlinear dependence on body weight. Demographic factors other than weight and age were not found to be influential in the model. Both clearance and distributional clearance were markedly different in the younger (< 2 years) or lighter (< 10 kg) patients, respectively. Thereafter the parameter values slowly approached those found in adults. In this study, a mean of 4.6 samples per patient was used to provide information on the pharmacokinetics and the determinants of the pharmacokinetic variability in infants and children. The findings in the younger, lighter patients, if generally applicable, might have significance for the dosage recommendations for drugs with narrow therapeutic indices.